<DOC>
	<DOCNO>NCT02899338</DOCNO>
	<brief_summary>To characterize compare pharmacokinetics assess safety BI 695501 single injection use either auto injector prefilled syringe .</brief_summary>
	<brief_title>Pharmakokinetics Safety BI 695501</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Age 18 65 year ( inclusive ) BMI &gt; 17.5 &lt; 35.0 kg/m2 Healthy male female subject , accord investigator´s assessment , base complete medical history include physical examination , vital sign ( blood pressure [ BP ] , pulse rate [ PR ] ) , 12lead ECG , clinical laboratory test . Subjects meet follow criterion : Surgically sterilize ( confirmed 6 month prior enrollment ) Have surgically sterilize sexual partner ( confirmed 6 month prior enrollment ) Postmenopausal , define least 1 year spontaneous amenorrhea ( questionable case blood sample simultaneous level FSH 40 U/L estradiol 30 ng/L confirmatory ) Subjects agree use adequate contraception , start begin trial 6 month dose trial drug : e.g . follow method plus condom : implant , injectables , combine oral vaginal contraceptive , intrauterine device Signed date write informed consent accordance GCP local legislation prior admission trial Exclusion criterion : Previous exposure adalimumab propose adalimumab biosimilar drug . Any finding medical examination ( include blood pressure ( BP ) , pulse rate ( PR ) electrocardiogram ( ECG ) ) deviate normal judge clinically relevant investigator . Any evidence concomitant disease judge clinically relevant investigator include gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , hormonal disorder diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder . History relevant orthostatic hypotension , faint spell , blackout . Chronic relevant acute infection . Positive result HIV , HBV , hepatitis C ( Hep C ) screen . History relevant allergy hypersensitivity include allergy trial medication , excipients device material ( e.g . natural rubber latex ) . Within 10 day prior administration trial medication , use drug might reasonably influence result trial . Intake investigational drug another trial within 2 month 5 halflives ( whichever longer ) prior plan administration trial medication trial intake investigational drug course trial . Alcohol abuse ( consumption 28 units/week ) . Unwillingness/inability refrain intake alcoholic beverage 48 hour prior trial medication administration Day 14 post trial medication administration ; and/or limit alcohol intake maximum 3 unit per day e.o.t . Drug abuse positive drug screening . Blood donation 500 mL within 30 day prior administration trial medication intend donation trial . Intention perform excessive physical activity within 4days prior administration trial medication contact sport entire trial unwilling avoid vigorous exercise 14 day post dose . Inability comply dietary regimen trial site . Any outofrange laboratory value consider clinically significant investigator ; ( subject creatine kinase ( CK ) value 2 time upper limit normal ( ULN ) Day 1 exclude participation ) . Subject assess unsuitable inclusion investigator , instance , consider able understand comply trial requirement , condition would allow safe participation trial . Subjects immunological disorder autoimmune disorder , ( e.g. , RA , lupus erythematosus , scleroderma , etc. ) . Subject receive live vaccine within 12 week prior enrol trial . History TB positive finding IGRA . Evidence skin irritation infection plan injection place . Currently enrol another investigational device drug study Any condition , investigator´s opinion , make unreliable study subject unlikely complete trial Women pregnant , nursing , plan become pregnant trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>